India-Specific Disease R&D

A drug discovered in India. Developed in India. Targeting a disease that still strikes 2.5 lakh Indians every year.Zydus Lifesciences just received DCGI approval to begin Phase III trials of Zintrodiazine a novel anti-malarial compound active against drug-resistant strains of both P. falciparum and P. vivax. This is a decade-long bet, built on a 2016 collaboration with Medicines for Malaria Venture, on a molecule originally discovered by MMV and AstraZeneca India. It is one of the most significant drug development milestones in Indian pharma in years.India has world-class manufacturing, deep scientific talent, and government schemes like PLI, PRIP, Biopharma SHAKTI, now pointing in the right direction. What it still lacks is a financial bridge that lets companies recover the cost of novel drug discovery in low-margin therapeutic areas. Without a Priority Review Voucher equivalent, or stronger innovation rewards for neglected disease R&D, Zydus’s bet remains an act of corporate conviction. It is admirable, but not yet a replicable model.For CXOs allocating R&D capital, investors pricing innovation premiums, and policymakers building India’s next chapter in biopharma, this story deserves your attention.Listen in! This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com